FeesSafety
Pluang+

Revolution Medicines' cancer drug Rasonque posts record $198M launch in 5 weeks, boosting valuation prospects.

Market News
21 Nov 2026, 03:36 WIB
Prosper Junior Bakiny
View Source
Bullish
Revolution Medicines' cancer drug Rasonque posts record $198M launch in 5 weeks, boosting valuation prospects.

Revolution Medicines' pancreatic cancer drug Rasonque achieved a historic launch, generating $198 million in revenue within five weeks after its late August approval. The drug outperformed standard chemotherapy in Phase 3 trials, doubling median survival to 13.2 months. With a market cap of $34.8 billion and projections of $3 billion revenue next year, the company’s valuation is supported by strong sales and a promising pipeline. Expansion into Europe and other markets is underway, making the stock a compelling buy for long-term investors despite some risks.

Revolution Medicines Inc. shares trade at USD 162.00 on Pluang as of Nov 21, 2026 04:11 WIB, showing a 1.61% gain in the last day. The stock's market cap on Pluang stands at $34.47 billion, closely matching the article's figure. Trading volume reached 3,351,151 shares, with equal buy and sell activity, reflecting balanced investor interest.

More News (RVMD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App